Abstract |
Anaemia due to chronic kidney disease (CKD) is common and may be managed with erythropoiesis stimulating agents and/or iron preparations. Iron preparations may be administered orally, intravenously or by intramuscular injection. Oral preparations pose a significant tablet burden on patients who are often taking multiple medications and may have undesirable gastrointestinal side effects. The existing intravenous preparation Venofer requires multiple doses of drug (typically 100-200 mg) at multiple clinic visits. The preparation Cosmofer may be given as a single dose, but this requires four to six hours to administer. For these reasons, their use in pre-dialysis patients remains limited in practice. The new intravenous iron preparation Ferric Carboxymaltose ( Ferinject) may be given as a single dose of up to 1000 mg (but not exceeding 15 mg/kg/week) as an infusion over 6-15 minutes. This offers a significant advance in the management of these patients. We describe our initial experience with using this drug in a non-dialysis patient population with chronic kidney disease.
|
Authors | Senyo Tagboto, Liz Cropper, June Turner, Karen Pugh-Clarke |
Journal | Journal of renal care
(J Ren Care)
Vol. 35
Issue 1
Pg. 18-23
(Mar 2009)
ISSN: 1755-6678 [Print] United States |
PMID | 19200274
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Ferric Compounds
- Hematinics
- ferric carboxymaltose
- Maltose
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Anemia
(etiology, prevention & control)
- Female
- Ferric Compounds
(administration & dosage)
- Hematinics
(administration & dosage)
- Humans
- Infusions, Intravenous
- Male
- Maltose
(administration & dosage, analogs & derivatives)
- Middle Aged
- Premedication
- Renal Dialysis
- Renal Insufficiency, Chronic
(complications, drug therapy)
|